T. Rowe Price Investment Management, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

T. Rowe Price Investment Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $717,204 - $1.13 Million	-35,400 Reduced 1.9%	1,824,387 $39.8 Million
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $3.39 Million - $5.02 Million	-141,781 Reduced 7.08%	1,859,787 $59.1 Million
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $102,690 - $158,940	-4,500 Reduced 0.22%	2,001,568 $48.8 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $117,395 - $148,006	4,631 Added 0.23%	2,006,068 $63.3 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $51 Million - $82.9 Million	2,001,437 New	2,001,437 $56.6 Million

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.